Movement Alert｜WuXi XDC Falls 3.04% in Regular Trading, Buyback Measures Fail to Offset Sector-Wide Selling Pressure

Market Focus05-27

On May 27, WuXi XDC (02268.HK) declined 3.04% in regular trading to 55.75 HKD/share, with turnover of approximately 86.31 million HKD, as intensive buyback plans from both the company and its parent failed to stem ongoing sector weakness.

On the news front, WuXi XDC previously announced a share repurchase plan of up to 100 million USD using internal funds, while parent company WuXi Biologics further disclosed a buyback plan of up to 400 million USD on May 26, bringing the combined group repurchase scale to 500 million USD. Despite the significant capital commitment signaling management confidence in intrinsic value, the measures have not effectively reversed downward price momentum amid broad-based selling across the Life Sciences Tools and Services sector.

Within the sector, WuXi Biologics fell 1.34%, WuXi AppTec dropped 1.55%, and XtalPi declined 2.99%, while GenScript Biotech rose 3.69%. Guotai Junan Securities maintained an Overweight rating on WuXi XDC with a target price of 84.38 HKD, citing strong ADC pipeline growth prospects and backlog orders of approximately 14.89 billion USD as of end-2025, representing 50.3% year-over-year growth.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1131560364?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-27 10:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131560364","market":"us","top_or_hot":-1,"title":"Movement Alert｜WuXi XDC Falls 3.04% in Regular Trading, Buyback Measures Fail to Offset Sector-Wide Selling Pressure","media":"Market Focus","content":"<p><p>On May 27, WuXi XDC (02268.HK) declined 3.04% in regular trading to 55.75 HKD/share, with turnover of approximately 86.31 million HKD, as intensive buyback plans from both the company and its parent failed to stem ongoing sector weakness.</p><p>On the news front, WuXi XDC previously announced a share repurchase plan of up to 100 million USD using internal funds, while parent company WuXi Biologics further disclosed a buyback plan of up to 400 million USD on May 26, bringing the combined group repurchase scale to 500 million USD. Despite the significant capital commitment signaling management confidence in intrinsic value, the measures have not effectively reversed downward price momentum amid broad-based selling across the Life Sciences Tools and Services sector.</p><p>Within the sector, WuXi Biologics fell 1.34%, WuXi AppTec dropped 1.55%, and XtalPi declined 2.99%, while GenScript Biotech rose 3.69%. Guotai Junan Securities maintained an Overweight rating on WuXi XDC with a target price of 84.38 HKD, citing strong ADC pipeline growth prospects and backlog orders of approximately 14.89 billion USD as of end-2025, representing 50.3% year-over-year growth.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜WuXi XDC Falls 3.04% in Regular Trading, Buyback Measures Fail to Offset Sector-Wide Selling Pressure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜WuXi XDC Falls 3.04% in Regular Trading, Buyback Measures Fail to Offset Sector-Wide Selling Pressure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-27 10:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 27, WuXi XDC (02268.HK) declined 3.04% in regular trading to 55.75 HKD/share, with turnover of approximately 86.31 million HKD, as intensive buyback plans from both the company and its parent failed to stem ongoing sector weakness.</p><p>On the news front, WuXi XDC previously announced a share repurchase plan of up to 100 million USD using internal funds, while parent company WuXi Biologics further disclosed a buyback plan of up to 400 million USD on May 26, bringing the combined group repurchase scale to 500 million USD. Despite the significant capital commitment signaling management confidence in intrinsic value, the measures have not effectively reversed downward price momentum amid broad-based selling across the Life Sciences Tools and Services sector.</p><p>Within the sector, WuXi Biologics fell 1.34%, WuXi AppTec dropped 1.55%, and XtalPi declined 2.99%, while GenScript Biotech rose 3.69%. Guotai Junan Securities maintained an Overweight rating on WuXi XDC with a target price of 84.38 HKD, citing strong ADC pipeline growth prospects and backlog orders of approximately 14.89 billion USD as of end-2025, representing 50.3% year-over-year growth.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02268","symbol_name":"药明合联","start_time":0,"source_url":"","article_id":"1131560364","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131560364","pubTimestamp":1779850763,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 27, WuXi XDC (02268.HK) declined 3.04% in regular trading to 55.75 HKD/share, with turnover of approximately 86.31 million HKD, as intensive buyback plans from both the company and its parent...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02268":"药明合联"},"translate_title":"动静提示|药明新地常规交易跌3.04%回购措施未能抵消全板块抛压","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02268":1},"content_text":"On May 27, WuXi XDC (02268.HK) declined 3.04% in regular trading to 55.75 HKD/share, with turnover of approximately 86.31 million HKD, as intensive buyback plans from both the company and its parent failed to stem ongoing sector weakness.On the news front, WuXi XDC previously announced a share repurchase plan of up to 100 million USD using internal funds, while parent company WuXi Biologics further disclosed a buyback plan of up to 400 million USD on May 26, bringing the combined group repurchase scale to 500 million USD. Despite the significant capital commitment signaling management confidence in intrinsic value, the measures have not effectively reversed downward price momentum amid broad-based selling across the Life Sciences Tools and Services sector.Within the sector, WuXi Biologics fell 1.34%, WuXi AppTec dropped 1.55%, and XtalPi declined 2.99%, while GenScript Biotech rose 3.69%. Guotai Junan Securities maintained an Overweight rating on WuXi XDC with a target price of 84.38 HKD, citing strong ADC pipeline growth prospects and backlog orders of approximately 14.89 billion USD as of end-2025, representing 50.3% year-over-year growth.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1131560364","isCrawlerRequest":true}